Subscribe
shutterstock_1935382585_valeriya_zankovych
Valeriya Zankovych / Shutterstock.com
9 March 2023FeaturesBiotechnologySarah Speight

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Big pharma is no stranger to controversy, and AbbVie is perhaps one of the most lambasted.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC weighs in on AbbVie antitrust litigation
22 June 2023   Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
FTC weighs in on AbbVie antitrust litigation
22 June 2023   Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

More on this story

Americas
FTC weighs in on AbbVie antitrust litigation
22 June 2023   Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Generics
Abbvie seeks to block copycat of endometriosis drug
4 April 2023   Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
ResMed voids sleep apnoea tech patent at PTAB
Novartis settles with licensee of blood cancer therapy day before trial
Biotech and healthcare expert returns to Latham & Watkins
Commercialising genomic tech in Nigeria
Medical company sees $452m trade secrets award cut by 87%
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Strategic IP protection for biotech-related GenAI